Antiangiogenic activity against Homo sapiens (human) HepG2 cells assessed as reduction in VEGF level at 55 uM from 24 to 48 hr by ELISA relative to control
|
Homo sapiens
|
None
|
|
Antiangiogenic activity against Homo sapiens (human) HCT116 cells assessed as reduction in VEGF level at 52.3 uM after 48 hr by ELISA relative to control
|
Homo sapiens
|
54.0
%
|
|
Antiangiogenic activity against Homo sapiens (human) HCT116 cells assessed as reduction in VEGF level at 52.3 uM after 24 hr by ELISA relative to control
|
Homo sapiens
|
39.0
%
|
|
Cytotoxicity against Homo sapiens (human) HepG2 cells assessed as DNA fragmentation at 55 uM from 24 to 48 hr by agarose gel electrophoresis
|
Homo sapiens
|
None
|
|
Cytotoxicity against Homo sapiens (human) HCT116 cells assessed as DNA fragmentation at 53.2 uM after 48 hr by agarose gel electrophoresis
|
Homo sapiens
|
None
|
|
Induction of apoptosis in Homo sapiens (human) HepG2 cells assessed as caspase9 cleavage at 55 uM at 16 hr by Western blot analysis
|
Homo sapiens
|
None
|
|
Induction of apoptosis in Homo sapiens (human) HCT116 cells assessed as caspase9 cleavage at 52.3 uM at 16 hr by Western blot analysis
|
Homo sapiens
|
None
|
|
Induction of apoptosis in Homo sapiens (human) HepG2 cells assessed as effect on Bcl2 level at 55 uM from 3 to 24 hr by Western blot analysis
|
Homo sapiens
|
None
|
|
Induction of apoptosis in Homo sapiens (human) HCT116 cells assessed as effect on Bcl2 level at 52.3 uM from 3 to 24 hr by Western blot analysis
|
Homo sapiens
|
None
|
|
Induction of cell cycle arrest in Homo sapiens (human) HepG2 cells assessed as G2/M phase cells at 55 uM at 48 hr by flow cytometric analysis (Rvb = 4 +/- 0.9 cells)
|
Homo sapiens
|
1.8
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HepG2 cells assessed as G2/M phase cells at 55 uM at 24 hr by flow cytometric analysis (Rvb = 4 +/- 0.9 cells)
|
Homo sapiens
|
2.1
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HepG2 cells assessed as G2/M phase cells at 55 uM at 16 hr by flow cytometric analysis (Rvb = 4 +/- 0.9 cells)
|
Homo sapiens
|
2.9
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HepG2 cells assessed as S phase cells at 55 uM at 48 hr by flow cytometric analysis (Rvb = 46.4 +/- 3.6 cells)
|
Homo sapiens
|
15.4
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HepG2 cells assessed as S phase cells at 55 uM at 24 hr by flow cytometric analysis (Rvb = 46.4 +/- 3.6 cells)
|
Homo sapiens
|
33.01
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HepG2 cells assessed as S phase cells at 55 uM at 16 hr by flow cytometric analysis (Rvb = 46.4 +/- 3.6 cells)
|
Homo sapiens
|
38.4
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HepG2 cells assessed as increase in G0/G1 phase cells at 55 uM at 48 hr by flow cytometric analysis relative to control
|
Homo sapiens
|
62.1
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HepG2 cells assessed as increase in G0/G1 phase cells at 55 uM at 24 hr by flow cytometric analysis relative to control
|
Homo sapiens
|
27.4
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HepG2 cells assessed as G0/G1 phase cells at 55 uM at 16 hr by flow cytometric analysis (Rvb = 50.4 +/- 1.7 cells)
|
Homo sapiens
|
60.0
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HCT116 cells assessed as G2/M phase cells at 52.3 uM at 48 hr by flow cytometric analysis (Rvb = 9.7 +/- 0.8 cells)
|
Homo sapiens
|
2.7
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HCT116 cells assessed as G2/M phase cells at 52.3 uM at 24 hr by flow cytometric analysis (Rvb = 9.7 +/- 0.8 cells)
|
Homo sapiens
|
4.4
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HCT116 cells assessed as G2/M phase cells at 52.3 uM at 16 hr by flow cytometric analysis (Rvb = 9.7 +/- 0.8 cells)
|
Homo sapiens
|
9.5
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HCT116 cells assessed as S phase cells at 52.3 uM at 48 hr by flow cytometric analysis (Rvb = 33.6 +/- 0.6 cells)
|
Homo sapiens
|
13.4
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HCT116 cells assessed as S phase cells at 52.3 uM at 24 hr by flow cytometric analysis (Rvb = 33.6 +/- 0.6 cells)
|
Homo sapiens
|
19.9
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HCT116 cells assessed as S phase cells at 52.3 uM at 16 hr by flow cytometric analysis (Rvb = 33.6 +/- 0.6 cells)
|
Homo sapiens
|
32.7
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HCT116 cells assessed as increase in G0/G1 phase cells at 52.3 uM at 48 hr by flow cytometric analysis relative to control
|
Homo sapiens
|
47.3
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HCT116 cells assessed as increase in G0/G1 phase cells at 52.3 uM at 24 hr by flow cytometric analysis relative to control
|
Homo sapiens
|
32.3
%
|
|
Induction of cell cycle arrest in Homo sapiens (human) HCT116 cells assessed as G0/G1 phase cells at 52.3 uM at 16 hr by flow cytometric analysis (Rvb = 58.2 +/- 3.7 cells)
|
Homo sapiens
|
58.7
%
|
|
Cytotoxicity against Homo sapiens (human) MCF7 cells at 20 to 100 uM by SRB assay
|
Homo sapiens
|
None
|
|
Cytotoxicity against Homo sapiens (human) HeLa cells at 20 to 100 uM by SRB assay
|
Homo sapiens
|
None
|
|
Cytotoxicity against Homo sapiens (human) HepG2 cells at 20 to 100 uM by SRB assay
|
Homo sapiens
|
None
|
|
Cytotoxicity against Homo sapiens (human) HCT116 cells at 20 to 100 uM by SRB assay
|
Homo sapiens
|
None
|
|
Cytotoxicity against Homo sapiens (human) MCF7 cells after 24 to 72 hr by SRB assay
|
Homo sapiens
|
None
|
|
Cytotoxicity against Homo sapiens (human) HeLa cells after 24 to 72 hr by SRB assay
|
Homo sapiens
|
None
|
|
Cytotoxicity against Homo sapiens (human) HepG2 cells after 24 to 72 hr by SRB assay
|
Homo sapiens
|
None
|
|
Cytotoxicity against Homo sapiens (human) HCT116 cells after 24 to 72 hr by SRB assay
|
Homo sapiens
|
None
|
|
Cytotoxicity against Homo sapiens (human) HepG2 cells after 48 hr by SRB assay
|
Homo sapiens
|
55000.0
nM
|
|
Cytotoxicity against Homo sapiens (human) HCT116 cells after 48 hr by SRB assay
|
Homo sapiens
|
52300.0
nM
|
|
Cytotoxicity against Homo sapiens (human) MCF7 cells at 100 uM after 24 hr by SRB assay
|
Homo sapiens
|
45.0
%
|
|
Cytotoxicity against Homo sapiens (human) HepG2 cells at 100 uM after 24 hr by SRB assay
|
Homo sapiens
|
55.0
%
|
|
Cytotoxicity against Homo sapiens (human) HeLa cells at 100 uM after 24 hr by SRB assay
|
Homo sapiens
|
65.0
%
|
|
Cytotoxicity against Homo sapiens (human) HCT116 cells at 100 uM after 24 hr by SRB assay
|
Homo sapiens
|
47.0
%
|
|
Cytotoxicity against Homo sapiens (human) MCF7 cells at 40 uM after 48 hr by SRB assay
|
Homo sapiens
|
14.0
%
|
|
Cytotoxicity against Homo sapiens (human) HepG2 cells at 40 uM after 72 hr by SRB assay
|
Homo sapiens
|
15.0
%
|
|
Cytotoxicity against Homo sapiens (human) HeLa cells at 40 uM after 72 hr by SRB assay
|
Homo sapiens
|
20.0
%
|
|
Cytotoxicity against Homo sapiens (human) HCT116 cells at 40 uM after 72 hr by SRB assay
|
Homo sapiens
|
48.0
%
|
|
Cytotoxicity against Homo sapiens (human) MCF7 cells at 20 uM after 72 hr by SRB assay
|
Homo sapiens
|
None
|
|
Cytotoxicity against Homo sapiens (human) HCT116 cells at 20 uM after 72 hr by SRB assay
|
Homo sapiens
|
None
|
|
Cytotoxicity against Homo sapiens (human) HeLa cells at 20 uM after 72 hr by SRB assay
|
Homo sapiens
|
None
|
|
Cytotoxicity against Homo sapiens (human) HepG2 cells at 20 uM after 72 hr by SRB assay
|
Homo sapiens
|
None
|
|